β-tubulin

Tubulin polymerization-IN-43 is an inhibitor of tubulin polymerisation.Tubulin polymerization-IN-43 has multiple effects, disrupting the cellular microtubule network by targeting the colchicine locus and promoting cell cycle arrest and apoptosis in leukaemia cells. Tubulin polymerisation-IN-43 has multiple effects, promoting leukaemia cell cycle arrest in G2/M phase and apoptosis by targeting Colchicine sites to disrupt the cellular microtubule network.

Tubulin inhibitor 24 is a potent compound that inhibits tubulin polymerization.

Tubulin inhibitor 32 is an orally active novel microtubule inhibitor with antiproliferative and antitumor activity, inhibits microtubule polymerization, induces apoptosis and cell cycle arrest in G2/M phase.

Tubulin inhibitor 35 (Tubulin IN 35) is a potent dual inhibitor of topoisomerase I and microtubule protein polymerization with antitumor activity, inhibits migration and invasion of MGC-803 and RKO cell lines, interrupts the cell cycle and induces apoptosis.

Tubulin inhibitor 6 (iHAP1) is an inhibitor of tubulin and a potent inhibitor of multiple cancer cell lines.

Tubulin Polymerization-IN-2 is a powerful anticancer agent that targets β-tubulin, exhibiting an IC 50 of 0.92 μM. It demonstrates promising efficacy against a range of cancer cell lines including leukemia, non-small cell lung, renal, prostate, and breast cancers [1].

Tubulin polymerization-IN-53 (compound 4b) inhibits β-tubulin polymerization, arrests the cell cycle at the G2 M stage, and demonstrates antiproliferative efficacy against the MDA-MB-231 cell line, with an IC50 value of 3.24 μM [1].

Tubulin polymerization-IN-9, a potent inhibitor of tubulin (IC50: 1.82 μM), arrests the cell cycle of K562 cells in the G2 M phase, induces apoptosis and mitochondrial depolarization, and exhibits strong anti-vascular and anti-tumor effects.

Tubulin polymerization-IN-29 is a potent inhibitor of microtubule protein polymerization and shows potent anti-proliferative effects.Tubulin polymerization-IN-29 induces cell cycle arrest in HeLa cells at G2/M phase.

Tubulin Inhibitor 36 (Compound 10) serves as a potent novel inhibitor of tubulin polymerization, which consequently induces apoptosis in glioblastoma cells, reflected by an IC50 value of 1.5±0.1 μM. Exhibiting significant anti-mitotic activity, this compound demonstrates anti-tumor potential, particularly useful in glioblastoma multiforme (GBM) research [1].

Tubulin Inhibitor 37 (Compound 12) effectively impedes tubulin aggregation (IC50 = 1.3 µM) and demonstrates antiproliferative activity against human tumor cell lines, showing promise for cancer research [1].

Tubulin Inhibitor 38 (Compound 14), a tetrazole-based agent, demonstrates significant antiproliferative effects by inducing mitotic arrest and blocking the cell cycle at the G2/M phase, ultimately triggering apoptosis. Administered at 100 nM for 24 hours, it shows considerable cytotoxicity and selectivity within HeLa, MCF7, and U87 MG cell lines [1].

Tubulin Inhibitor 33 is a dose-dependent inhibitor of tubulin polymerization, exhibiting an IC50 value of 9.05 μM. This compound demonstrates antitumor activity and induces apoptosis, making it useful for antitumor research [1].

Tubulin polymerization-IN-45, a tubulin-targeting agent, inhibits tubulin polymerization by binding to tubulin's colchicine site, inducing apoptotic cell death in hepatocellular cancer (HCC) cells [1].

Tubulin polymerization-IN-46 (compound 9q) is a microtubule tubulin inhibitor that obstructs tubulin polymerization, triggers apoptosis, and arrests MCF-7 breast cancer cells in the G2 M phase, demonstrating potent anti-proliferative activity with an IC50 of 10 nM [1].

Tubulin inhibitor 14 is a potent inhibitor of NQO2 (quinone oxidoreductase 2) with an IC50 of 1.0 μM, which also inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. As a microtubule destabilizer, Tubulin inhibitor 14 has potential tumor-selective, anti-angiogenic, and vascular-destructive properties [1].

Tubulin polymerization-IN-35 is [1,2] an inhibitor of oxazolylisoindole microtubulin polymerization that acts highly selectively on the marginal zone lymphoma VL51 cell line.

Tubulin polymerization-IN-14 (Compound 20a) is a tubulin polymerization inhibitor (IC50 = 3.15 μM) that demonstrates strong anti-vascular and anticancer activities, including inducing cancer cell apoptosis [1].

Tubulin polymerization-IN-39, a tubulin polymerization inhibitor with an IC50 of 4.9 μM, targets the colchicine-binding site to hinder tubulin polymerization. This compound effectively suppresses cancer cell proliferation.

IDO Tubulin-IN-2 (HT2) is a potent inhibitor of TDO and tubulin, showing significant efficacy against cancer cell lines U87, HepG2, A549, HCT-116, and LO2, with respective IC50 values of 0.43, 0.036, 0.041, 0.095, and 1.04 μM. Additionally, IDO Tubulin-IN-2 markedly enhances antitumor activity [1].

Tubulin polymerization-IN-32 is a tubulin polymerization inhibitor that impedes cancer cell proliferation, making it a valuable tool for researching cancers, including lymphoma.

Tubulin polymerization-IN-26 (compound 12h) is a chemical compound that inhibits the polymerization of microtubulin by binding to the colchicine binding site, with an IC50 value of 4.64 μM. It can induce apoptosis and inhibit cell metastasis, making it a valuable compound for researching lung cancer [1].

Tubulin Polymerization-IN-51 (compound 7u) serves as a tubulin polymerization inhibitor, exhibiting an IC50 range of 2.55 - 17.89μM against SK-Mel-28 cells, and is applicable in cancer research [1].

Tubulin polymerization-IN-21 is an inhibitor of microtubulin polymerization that disrupts cell integrity and affects glucose metabolism, and has anticancer effects.

Tubulin polymerization-IN-25 is a selective, dual tubulin polymerization (IC50: 1.11 μM) and farnesyl transferase (FTase) (IC50: 0.39 μM) inhibitor. polymerization-IN-25 exhibits cytotoxicity against cancer cells and blocks cell proliferation.

Tubulin inhibitor 29 (compound 3c) is a potent tubulin inhibitor that disrupts tubulin assembly by binding at the colchicine site (IC50 = 1.2 μM), and exhibits antiproliferative effects on MCF-7 cells with an IC50 value of 7.5 μM. [1].

Tubulin inhibitor 17 (Compound 3b) is an inhibitor of tubulin polymerization (IC50 = 12.38 µM) that exhibits anticancer activities and induces cell apoptosis[1].

Tubulin polymerization-IN-42 (compound 10j), an indole-substituted furanone, inhibits tubulin polymerization and exhibits anti-cancer properties [1].

Tubulin HDAC-IN-2 (Compound II-19k) is a dual inhibitor of Tubulin and HDAC, with IC50 values of 0.403 μM for HDAC1, 0.591 μM for HDAC2, 3.552 μM for HDAC3, and 0.459 μM for HDAC6. The compound induces G2 phase cell cycle arrest, promotes apoptosis, hampers hematoma and solid tumor cell proliferation, diminishes tumor metastasis, and inhibits tumor growth in a liver tumor allograft mouse model [1].

Tubulin polymerization-IN-52 (compound SC23) effectively inhibits tubulin polymerization with an IC50 value of 2.9 μM [1].

Tubulin polymerization-IN-6 (compound 5f) is a potent tubulin polymerization inhibitor with an IC50 of 1.09 μM. It inhibits cell migration and tube formation, exhibits anti-angiogenic properties, and effectively hinders tumor growth in HT29 xenograft Balb c nude mice [1].

Tubulin polymerization-IN-31 (Compound 4c) is an inhibitor of tubulin polymerization with an IC50 value of 3.64 μM [1], exhibiting antitumor activity and inducing apoptosis in cancer cells.

Tubulin polymerization-IN-8 (compound IIc) is a potent inhibitor of tubulin polymerization, inducing concentration-dependent cell cycle arrest at the G2 M phase in HCT116 tumor cells and significantly inhibiting tubulin polymerization with an IC50 of 12.7 μM, showing potential for cancer research [1].

Tubulin polymerization-IN-33, an [1,2] inhibitor of oxazoloisoindole microtubulin polymerization, is an effective anti-proliferative agent for NCI series cancer cells.

Tubulin inhibitor 23 is a potent tubulin inhibitor (IC50: 4.8 μM) that exhibits antiangiogenic effects in a dose-dependent manner and induces apoptosis. This compound shows potential for leukemia research.

Tubulin inhibitor 20 (compound 1) exhibits significant potential for cancer research as a potent tubulin inhibitor [1].

Tubulin Inhibitor 11 is a potent, orally active agent that inhibits tubulin by targeting the Colchicine binding site. It impedes tubulin polymerization, leading to mitotic blockade and apoptosis.

Tubulin polymerization-IN-10 is a highly potent inhibitor of tubulin polymerization with an IC50 value of 4.25±0.75 μM, exhibiting significant anti-tumor properties [1].

Tubulin inhibitor 19 (compound 9b) is a potent indole chalcone compound exhibiting strong tubulin inhibitory activity, making it valuable for cancer research [1].

Tubulin Inhibitor 27 (DYT-1), a compound that inhibits tubulin polymerization with an IC50 of 25.6 μM, exhibits anti-angiogenesis and antitumor activities [1].

Tubulin JAK2-IN-1 (compound 7g) is a potent dual inhibitor of Janus kinase 2 (JAK2) and microtubules, exhibiting significant antiproliferative effects against cancer cells [1].

αβ-Tubulin-IN-1 is a potent, orally active inhibitor of αβ-Tubulin that blocks the cell cycle at the G2 M phase and induces apoptosis. It inhibits tumor cell migration and metastasis, exhibiting significant antitumor efficacy.

Tubulin polymerization-IN-13 (Compound 4f) is a potent tubulin polymerization inhibitor with an IC50 of 0.37 μM, demonstrating significant anti-proliferative effects on cancer cells, inducing apoptosis, and exhibiting potential antivascular activity [1].

Tubulin polymerization-IN-22 arrests cell cycle at G2 M phase as well as induces apoptosis. Tubulin polymerization-IN-22 is an inhibitor of tubulin polymerization (IC 50 = 8.1 μM) [1].

Tubulin polymerization-IN-34 is an inhibitor of [1,2] oxazolylisoindole-based microtubule polymerization and demonstrates high selectivity for marginal zone lymphoma VL51 cell lines.

Tubulin polymerization-IN-4 is an effective inhibitor of tubulin polymerization (IC50=4.6 μM）。 Tubulin polymerization-IN-4 can destroy tubulin polymerization, block cell cycle at G2 M phase, induce apoptosis, and inhibit cell cloning and migration. Tubulin polymerization-IN-4 can also damage the vascular system.